Sun Pharmaceutical Industries Limited has announced the schedule for its fourth quarter earnings release and investor conference call. The company will publish its financial results for the quarter ended 31 March 2026 on 22 May 2026, with results also made available on the company website at www.sunpharma.com . The announcement was communicated to stock exchanges on 13 May 2026.

Earnings Call Details

The company will conduct an hour-long earnings conference call at 06.30 pm IST on 22 May 2026, where senior management will discuss the company's performance and answer questions from participants. Investors are advised to pre-register and dial in five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call begins. The call may also be accessed via an audio webcast, details of which will be announced on the company website. A transcript of the conference call will also be made available on the company website following the event.

The following table summarises the key events and participation details:

About Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries is described as the world's leading specialty generics company, with a presence across Innovative Medicines, Generics, and Consumer Healthcare products. It is the largest pharmaceutical company in India and a leading generic company in the US as well as Global Emerging Markets. The company's Global Innovative Medicines portfolio spans dermatology, ophthalmology, and onco-dermatology, and accounts for about 20% of company sales.

Key highlights of the company's profile include:

• Geographic reach: Medicines trusted by physicians and consumers in over 100 countries
• Manufacturing: Facilities spread across five continents
• Workforce: Multi-cultural workforce drawn from over 50 nations
• Vertically integrated operations delivering high-quality medicines across therapeutic segments

Investor and Media Contacts

For further information, stakeholders may reach out through the following contacts:

The regulatory filing was signed by Anoop Deshpande, Company Secretary and Compliance Officer (ICSI Membership No.: A23983), on 13 May 2026.

The Board of Directors of Sun Pharmaceutical Industries Limited has approved the appointment of Dr. Andreas Eugen Busch (DIN: 11699735) as an Independent Director for a term of five consecutive years, effective 12 May 2026, subject to the approval of shareholders. The decision was passed by a board resolution on 12 May 2026 and disclosed to stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Part A of Schedule III.

Profile of the Incoming Independent Director

Dr. Busch is a globally recognised leader in drug discovery and pharmaceutical R&D. He is presently serving as Chief Innovation Officer at Absci, where he is responsible for leading R&D, technical operations, and driving both internal and partner programs. His career spans senior R&D leadership roles at some of the world's foremost pharmaceutical companies, including Sanofi, Bayer, and Shire. His leadership has resulted in over 15 commercial drugs progressing from bench research to FDA approval, with several more in late-stage clinical development. Dr. Busch also holds the title of Extraordinary Professor of Pharmacology at the Johann Wolfgang Goethe-University in Frankfurt, Germany, where he received his PhD in Pharmacology.

The key details of his appointment, as disclosed under the regulatory framework, are summarised below:

Committee Reconstitution

In a related development, the Board also approved changes to the composition of its committees. Following earlier intimations dated 31 January 2026, 04 April 2026, and 08 May 2026, Ms. Rama Bijapurkar is set to retire from the Board on 20 May 2026 upon completion of her term as an Independent Director. To ensure continuity in governance, the Board approved the appointment of Ms. Satyavati Berera (DIN: 05002709) as a member of both the Audit Committee and the Risk Management Committee, effective 12 May 2026.

Regulatory Compliance

The disclosures pertaining to Dr. Busch's appointment confirm that he is not related to any Director, Key Managerial Personnel, or promoter of Sun Pharmaceutical Industries Limited, and does not have any inter se relationship with any of the Directors of the Company. Additionally, he is not debarred from holding the office of Director pursuant to any order of SEBI or any other such authority, in accordance with BSE Circular ref. no. LIST/COMP/14/2018-19 and NSE ref. no. NSE/CML/2018/24, both dated 20 June 2018. The regulatory filing was signed by Anoop Deshpande, Company Secretary and Compliance Officer (ICSI Membership No.: A23983).